Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,996
  • Shares Outstanding, K 8,307
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade LSTA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 2
  • High Estimate -0.71
  • Low Estimate -0.74
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +5.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +3.77%
on 04/23/24
3.27 -19.03%
on 03/28/24
-0.53 (-16.55%)
since 03/26/24
3-Month
2.42 +9.41%
on 01/29/24
3.40 -22.12%
on 03/21/24
-0.19 (-6.77%)
since 01/26/24
52-Week
1.95 +35.78%
on 09/15/23
4.53 -41.59%
on 06/14/23
-0.54 (-16.87%)
since 04/26/23

Most Recent Stories

More News
Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

/PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the...

LSTA : 2.65 (-0.46%)
Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

PRGO : 31.94 (+2.14%)
ADAP : 1.0750 (+1.42%)
SPRO : 1.4600 (+2.10%)
LSTA : 2.65 (-0.46%)
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

ADAP : 1.0750 (+1.42%)
SPRO : 1.4600 (+2.10%)
KRTX : 329.83 (+0.03%)
LSTA : 2.65 (-0.46%)
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

AGIO : 31.49 (-0.57%)
ADAP : 1.0750 (+1.42%)
SPRO : 1.4600 (+2.10%)
LSTA : 2.65 (-0.46%)
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

MRK : 131.20 (+0.37%)
MRNA : 107.97 (+1.69%)
SPRO : 1.4600 (+2.10%)
LSTA : 2.65 (-0.46%)
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss

Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.

ADAP : 1.0750 (+1.42%)
SPRO : 1.4600 (+2.10%)
ALLO : 2.89 (+1.23%)
LSTA : 2.65 (-0.46%)
Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug

The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.

NVS : 97.44 (-1.64%)
BMY : 44.85 (+0.34%)
AMGN : 269.98 (+0.22%)
LSTA : 2.65 (-0.46%)
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence

Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.

MRK : 131.20 (+0.37%)
MRNA : 107.97 (+1.69%)
LGND : 70.57 (+0.28%)
LSTA : 2.65 (-0.46%)
4 Medical Stocks to Buy as Rate Hike Cycle Nears End

We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.

PRE : 4.61 (-7.24%)
HROW : 10.53 (+5.30%)
OCUP : 1.6100 (+4.89%)
LSTA : 2.65 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 2.93
2nd Resistance Point 2.86
1st Resistance Point 2.75
Last Price 2.65
1st Support Level 2.57
2nd Support Level 2.50
3rd Support Level 2.40

See More

52-Week High 4.53
Fibonacci 61.8% 3.55
Fibonacci 50% 3.24
Fibonacci 38.2% 2.94
Last Price 2.65
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar